Healthy volunteers needed to Taste-Test a new drug pill
NCT ID NCT07453784
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new, smaller minitablet version of the drug obefazimod in 44 healthy adults aged 18 to 55. The goal is to see how the body absorbs the minitablet compared to the current capsule and to check if the minitablet tastes okay. Participants will take a single dose and have their blood levels measured. This is not a treatment study—it helps develop a child-friendly pill form.
Why investors are watching
Abivax is testing a new minitablet version of its drug obefazimod in 44 healthy adults. The study checks whether the minitablet delivers the same drug levels as the existing capsule and whether people find it palatable. For a small company, this readout matters because a positive result supports a pediatric formulation, which could broaden the drug's use beyond adults.
If it works: If the minitablet matches the capsule's drug exposure and tastes acceptable, Abivax can advance it toward studies in children. That could expand the drug's market to pediatric patients, a meaningful step for a small-cap company.
If it fails: If the minitablet shows poor absorption or is unpalatable, Abivax may need to reformulate, delaying pediatric development. Phase 1 trials in healthy volunteers often fail to translate to later stages, so a setback here would not be unusual.
AI-written from the trial record. Speculative, and not investment advice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 44 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2026
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aged 18 to 55 years inclusive at the time of signing informed consent * Must agree to adhere to the contraception requirements. * Healthy male or non-pregnant, non-lactating female participants according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs, 12-lead ECG and laboratory safety tests without any clinically significant abnormalities * Body mass index (BMI) of 18.0 to 32.0 kg/m2 as measured at screening * Weight ≥50 kg at screening Inclusion criteria. Exclusion Criteria: * Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. * History of clinically significant cardiovascular, renal, hepatic, dermatological, respiratory or GI disease, neurological or psychiatric disorder, as judged by the investigator * Participants with a history of cholecystectomy or gall stones * Participants with chronic or recurrent infection * Participants who have tested positive for tuberculosis * Participants with a history of shingles within the last two months * History of opportunistic infection while not on immunosuppressive therapy * Part 2 only: Participant has a medical condition that may adversely affect taste or smell activity including but not limited to mouth ulcers, significant gum disease, and respiratory and/or sinus infection or cold * Part 2 only: Participant does not agree to the consumption of, or has any known allergies to any of the food vehicles used in this study (applesauce, chocolate pudding, yogurt) * Participants who have received any IMP (Investigational Medicinal Product) in a clinical research study within the 90 days prior to Day 1, or less than 5 elimination half-lives prior to Day 1, whichever is longer * Participants who have previously been administered IMP in this study * Donation of blood or plasma within the previous 3 months or loss of greater than 400 mL of blood * Participants who are taking, or have taken, any prescribed or over-the-counter drug, hormone replacement therapy (HRT) or herbal remedies (other than up to 4 g of paracetamol per day and hormonal contraception) in the 14 days or 5 elimination half-lives, whichever is longer, before first IMP administration (see Section 11.4). Exceptions may apply, as determined by the investigator * Having any vaccination or planned vaccination within 28 days before Day 1. Participants who received live vaccine within 3 months prior to screening and/or who are planning to receive such a vaccine during the study duration. * History of any drug or alcohol abuse in the past 2 years * Regular alcohol consumption in males \>21 units per week and in females \>14 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type) * Current smokers and those who have smoked within the last 12 months * Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months * Confirmed positive drugs of abuse test result at screening or admission
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Quotient Sciences
RECRUITINGNottingham, NG11 6JS, United Kingdom
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a protein powder with creatine and fiber boost everyday Well-Being?
- Green tech or hidden stress? bus Drivers' hearts monitored behind the wheel
- Shout it out: can growls and screams raise pain tolerance?
- Scientists probe why brain stimulation works for some and not others
- Tiny doses, big questions: how does the body handle this prodrug?
- First human test of CM583: can this biologic pass the safety check?